Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: AMRN stock price vs RHI: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at RHI's multiple
Needs RHI P/S.
Implied fair value · at AMRN's multiple
Needs AMRN P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: AMRN FY 2025 (ended Dec 31, 2025) · RHI FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
AMARIN CORP PLC\UK · implied price per share
Bear
-$0.42
Base
-$0.49
Bull
-$0.56
ROBERT HALF INC. · implied price per share
Bear
$1.83
Base
$2.15
Bull
$2.48
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.22x
0.00x
Net debt / EBITDA
Leverage against operating earnings
6.57x
-1.88x
Cash and equivalents
Liquid reserves on the balance sheet
$302.59M
$464.44M
Total debt
Interest-bearing obligations outstanding
$99.83M
$696.00K
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LIGAND PHARMACEUTICALS INC
AMRN vs LGND
Harmony Biosciences Holdings, Inc.
AMRN vs HRMY
SUPERNUS PHARMACEUTICALS, INC.
AMRN vs SUPN
Viatris Inc
AMRN vs VTRS
Organon & Co.
AMRN vs OGN
INCYTE CORP
AMRN vs INCY
ManpowerGroup Inc.
AMRN vs MAN
INSPERITY, INC.
AMRN vs NSP
Accenture plc
AMRN vs ACN
MARSH & MCLENNAN COMPANIES, INC.
AMRN vs MMC
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe AMRN can rapidly improve profitability and sustain a much higher valuation multiple than RHI despite current losses, then hold only with caution; otherwise, the data supports avoiding or underweighting AMRN because its 32.2x P/S and 31.2x EV/Revenue are not backed by current margins, returns, or earnings.
AMRN trades at a massive premium to RHI on both revenue and earnings-based valuation, yet RHI-implied value is only about $0.32-$0.33 versus AMRN's current $16.37. The gap is driven by AMRN's 32.2x P/S and 31.2x EV/Revenue versus RHI's 0.6x on both measures, indicating the market is pricing in far stronger business quality than the operating data supports.
Supporting Metrics
Live quote
